Akebia Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Akebia Therapeutics entered into a senior secured term loan with Symbiotic Capital on November 12, 2026, consisting of an initial $60 million tranche (fully funded) plus an optional $80 million incremental tranche at Symbiotic's discretion. Proceeds from the initial tranche were used to fully repay the $55 million BlackRock loan facility. The new facility carries a 60-month maturity with interest-only for 60 months (variable rate: greater of WSJ Prime + 4.5% or 11.5%). Management reaffirmed at least two years of cash runway.
Why this rating
Refinancing replaces maturing debt; $60M equals ~6% of market cap. Non-dilutive but higher interest rates signal tighter credit access. Cash runway reaffirmation provides stability.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.